• Je něco špatně v tomto záznamu ?

CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis

M. Roblek, D. Protsyuk, PF. Becker, C. Stefanescu, C. Gorzelanny, JF. Glaus Garzon, L. Knopfova, M. Heikenwalder, B. Luckow, SW. Schneider, L. Borsig,

. 2019 ; 17 (3) : 783-793. [pub] 20181214

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006686

Increased levels of the chemokine CCL2 in cancer patients are associated with poor prognosis. Experimental evidence suggests that CCL2 correlates with inflammatory monocyte recruitment and induction of vascular activation, but the functionality remains open. Here, we show that endothelial Ccr2 facilitates pulmonary metastasis using an endothelial-specific Ccr2-deficient mouse model (Ccr2ecKO). Similar levels of circulating monocytes and equal leukocyte recruitment to metastatic lesions of Ccr2ecKO and Ccr2fl/fl littermates were observed. The absence of endothelial Ccr2 strongly reduced pulmonary metastasis, while the primary tumor growth was unaffected. Despite a comparable cytokine milieu in Ccr2ecKO and Ccr2fl/fl littermates the absence of vascular permeability induction was observed only in Ccr2ecKO mice. CCL2 stimulation of pulmonary endothelial cells resulted in increased phosphorylation of MLC2, endothelial cell retraction, and vascular leakiness that was blocked by an addition of a CCR2 inhibitor. These data demonstrate that endothelial CCR2 expression is required for tumor cell extravasation and pulmonary metastasis. IMPLICATIONS: The findings provide mechanistic insight into how CCL2-CCR2 signaling in endothelial cells promotes their activation through myosin light chain phosphorylation, resulting in endothelial retraction and enhanced tumor cell migration and metastasis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006686
003      
CZ-PrNML
005      
20200526084401.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1541-7786.MCR-18-0530 $2 doi
035    __
$a (PubMed)30552233
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Roblek, Marko $u Institute of Physiology, University of Zurich and Zurich Center for Integrative Human Physiology, Zurich, Switzerland.
245    10
$a CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis / $c M. Roblek, D. Protsyuk, PF. Becker, C. Stefanescu, C. Gorzelanny, JF. Glaus Garzon, L. Knopfova, M. Heikenwalder, B. Luckow, SW. Schneider, L. Borsig,
520    9_
$a Increased levels of the chemokine CCL2 in cancer patients are associated with poor prognosis. Experimental evidence suggests that CCL2 correlates with inflammatory monocyte recruitment and induction of vascular activation, but the functionality remains open. Here, we show that endothelial Ccr2 facilitates pulmonary metastasis using an endothelial-specific Ccr2-deficient mouse model (Ccr2ecKO). Similar levels of circulating monocytes and equal leukocyte recruitment to metastatic lesions of Ccr2ecKO and Ccr2fl/fl littermates were observed. The absence of endothelial Ccr2 strongly reduced pulmonary metastasis, while the primary tumor growth was unaffected. Despite a comparable cytokine milieu in Ccr2ecKO and Ccr2fl/fl littermates the absence of vascular permeability induction was observed only in Ccr2ecKO mice. CCL2 stimulation of pulmonary endothelial cells resulted in increased phosphorylation of MLC2, endothelial cell retraction, and vascular leakiness that was blocked by an addition of a CCR2 inhibitor. These data demonstrate that endothelial CCR2 expression is required for tumor cell extravasation and pulmonary metastasis. IMPLICATIONS: The findings provide mechanistic insight into how CCL2-CCR2 signaling in endothelial cells promotes their activation through myosin light chain phosphorylation, resulting in endothelial retraction and enhanced tumor cell migration and metastasis.
650    _2
$a zvířata $7 D000818
650    _2
$a kapilární permeabilita $7 D002199
650    _2
$a karcinom plic Lewisové $x krevní zásobení $x metabolismus $x patologie $x sekundární $7 D018827
650    _2
$a pohyb buněk $x fyziologie $7 D002465
650    _2
$a chemokin CCL2 $x metabolismus $7 D018932
650    _2
$a endoteliální buňky $x metabolismus $x patologie $7 D042783
650    _2
$a nádory plic $x krevní zásobení $x metabolismus $x patologie $x sekundární $7 D008175
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a lehké řetězce myosinu $x metabolismus $7 D018994
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a receptory CCR2 $x metabolismus $7 D054390
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Protsyuk, Darya $u Institute of Physiology, University of Zurich and Zurich Center for Integrative Human Physiology, Zurich, Switzerland.
700    1_
$a Becker, Paul F $u Institute of Virology, Technische Universität München/Helmholtz Zentrum Munich, Munich, Germany.
700    1_
$a Stefanescu, Cristina $u Institute of Physiology, University of Zurich and Zurich Center for Integrative Human Physiology, Zurich, Switzerland.
700    1_
$a Gorzelanny, Christian $u Department of Dermatology and Venerology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Glaus Garzon, Jesus F $u Institute of Physiology, University of Zurich and Zurich Center for Integrative Human Physiology, Zurich, Switzerland.
700    1_
$a Knopfova, Lucia $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Center, Center for Biological and Cellular Engineering, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Heikenwalder, Mathias $u Institute of Virology, Technische Universität München/Helmholtz Zentrum Munich, Munich, Germany. German Cancer Research Centre (DKFZ), Division of Chronic Inflammation and Cancer, Heidelberg, Germany.
700    1_
$a Luckow, Bruno $u Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany.
700    1_
$a Schneider, Stefan W $u Department of Dermatology and Venerology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Borsig, Lubor $u Institute of Physiology, University of Zurich and Zurich Center for Integrative Human Physiology, Zurich, Switzerland. lborsig@access.uzh.ch.
773    0_
$w MED00007101 $t Molecular cancer research : MCR $x 1557-3125 $g Roč. 17, č. 3 (2019), s. 783-793
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30552233 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526084358 $b ABA008
999    __
$a ok $b bmc $g 1525544 $s 1096742
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 17 $c 3 $d 783-793 $e 20181214 $i 1557-3125 $m Molecular cancer research $n Mol Cancer Res $x MED00007101
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace